DocGo Inc. (DCGO) Earnings Call Transcript & Summary
August 7, 2023
Earnings Call Speaker Segments
Mike Cole
executiveThank you, Operator. Before I hand things over to management, I'd like to offer a few comments about forward-looking statements. Everything discussed on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions may be used to flag these forward-looking statements. Such forward-looking statements don't guarantee future performance, results, or outcomes, and they may involve and are subject to certain risks and uncertainties along with other factors that could affect DocGo's business, financial condition, and other operating results. These cover—though aren't restricted to—the risk factors and additional qualifications found in DocGo's Form 10-K annual report, Form 10-Q quarterly filings, and further reports and statements the company submits to the SEC, which you should review carefully. What actually happens and the results achieved may diverge substantially from anything such forward-looking statements state or suggest. References to non-GAAP financial measures appear in today's call. You'll find reconciliations of those non-GAAP figures against the closest comparable GAAP measures either supplied as part of this call or included in our earnings release, available on our website, docgo.com, and also filed with the Securities and Exchange Commission. What's shared on this call holds true only as of today's date. Listeners shouldn't expect those remarks to stay valid or applicable afterward. We're not committing to refresh anything covered here—whether because of fresh details, coming developments, or other reasons—unless the law demands it. With that, I'm glad to hand things over to DocGo's CEO, Mr. Anthony Capone. Anthony, the floor is yours.
Anthony Capone
executiveThanks, Mike, and thanks to everyone for being with us today. We had a really strong second quarter, and momentum has picked up considerably, which positions us well for significant growth going forward. We not only achieved a record high in quarterly revenues, but just as importantly, we produced increasingly positive patient outcomes for people facing the greatest need. Because demand has been strong across every area, we're lifting our full year 2023 revenue guidance to $540 million-$550 million from $500 million-$510 million, and raising our Adjusted EBITDA guidance to $48 million-$53 million from $45 million-$50 million. Several factors are fueling this sharp acceleration in revenue growth, among them the ongoing rollout of our medical transportation contract with NYC Health + Hospitals and the new mobile health contract with the Housing and Preservation Department to deliver primary care, urgent care, behavioral health, social work, and other supporting services to migrant populations in New York. Very recently, we were awarded mobile health contracts for flu vaccination programs in South Carolina and a municipal employer health deal in Orange County. Although the revenues tied to these are minimal in the near term, they have substantial growth potential. These are the kinds of programs we believe will help us build a greater mobile health presence in relatively new geographies, and our aim is to expand on that over time; the raised guidance is prudent and reflects a mix of new contract wins plus the current run rate of existing contracts, not necessarily their full potential as they scale. Everything we're seeing suggests substantial acceleration in the near term, and as we gain more visibility, we'll update guidance, if applicable, over the balance of the year. Given its current growth rate, we anticipate it's possible for us to reach the maximum value of the contract, less an estimated $120 million tied to subcontracting services, which will not flow through our financials. It's worth emphasizing that no other company we've ever come across possesses the workforce, technology, and experience to deploy mobile health programs rapidly at this scale in response to an unprecedented emergent crisis, not to mention the balance sheet needed to support the accelerated launch of such programs. Both our customer and employee satisfaction stand at all-time highs; on a scale from — 100 to 100, our on-demand customer NPS for Q2 came in at an 89. In addition, over the trailing 12 months, our employee retention has improved by over 100%. That doubling of retention is further reinforced by more than 240 promotions we've made just this year, helping support clinicians who operate today as individual providers to grow into meaningful management careers; with an industry-leading Glassdoor score of 4.2 and an Indeed score of 4.3, it's clear our employees love working at DocGo. At this point, I'll hand the call over to Lee Bienstock, our President and COO, for some operational details. Lee, please go ahead.
Lee Bienstock
executiveAnthony, thanks. Ahead of covering those operational details, I want to note some great news: we reached a significant milestone in Q2. Our Street Health Outreach and Wellness program, which we operate alongside NYC Health + Hospitals, has now gone beyond 300,000 patient interactions. That flagship effort brings medical care and mental health services to people experiencing unsheltered homelessness, and hitting this mark fills us with real pride. The $432 million mobile health contract with HPD that Anthony mentioned earlier didn't contribute much in Q2, but we see enormous potential there for the remainder of the year and far beyond. DocGo received that contract through an emergency authorization, following several years of successful work with the city across numerous contracts, which built up our track record and earned the city's trust. Our innovative clinical delivery model, our technology, and our highly sophisticated operational models let us provide these services in a way that's both cost-efficient and high quality. Over the quarter, we made considerable headway in continuing to evolve our business model and in launching care gap closure programs with four new major payers. Before getting into those specifics, I want to explain how our strategy with payers has changed. Initially, these partnerships typically started in a fairly straightforward way—as an in-network supplier of routine healthcare services, which were exposed to fluctuations in demand. We viewed that as a means of demonstrating DocGo's clinical capabilities to our payer partners, and those partnerships are now developing into focused programs for closing care gaps, intended to deliver preventive care and to treat at-risk and chronically ill patients. Under these new arrangements, there's a set fee for each visit plus assured minimums, and DocGo gets a roster of high-risk and chronically ill patients from our national operations center in Tuscaloosa, Alabama, which reaches out to them and books particular medical services. In other words, rather than DocGo sitting back until patients get in touch with us, patients are now handed to us directly; among the services are bone density tests, diabetic retinal exams, and mobile EKGs, to cite just a few. All told, we anticipate that these four payers will hand us 73,000 patients in need of care gap closure and primary care services. In our view, preventative care saves lives, lifts program quality measures, and helps patients stay out of the hospital. We're really enthusiastic about this space, and we anticipate sharing more progress with those prominent partners soon. A key driver of the robust demand in our mobile health segment is the very persuasive outcomes emerging from our initial collaborations. In the post-discharge program we run with LA Care, we found that more than half of patients had discharge medications and orders that were wrong or absent — roughly in line with the national rate. Those patients typically wait about three weeks on average for a follow-up appointment with their PCP or a specialist, whereas we can be brought in to address these problems much more quickly and proactively. To give you another illustration, during the last 60 days, we finished over 200 diabetic screenings — diabetic eye exams, blood glucose checks, and blood pressure control screenings — together with a large Medicaid plan, via a program we recently launched. At the time we saw them, more than 20% of these patients had A1C levels above nine, indicating poor diabetes control and a risk factor for complications, including potential renal failure, blindness, and neurologic damage; collaborating with their PCPs, we could assist these patients, or supply additional treatment or medication changes. The data and impact we're observing strengthen our conviction that DocGo is uniquely positioned to drive improved patient outcomes while lowering costs for payers. Our virtual care management program has likewise shown impressive expansion, and at present we work with eight customer clinics delivering care throughout every stage of virtual care management, covering remote physiologic monitoring as well as principal care management. Over the past six weeks, the count of patients being monitored has climbed 300%. We have now entered the contracting stage with six sizable nephrology practices that reached us via our strategic partnership with Fresenius Medical Care. Those practices involve hundreds of nephrologists overseeing tens of thousands of patients. During the second quarter, we achieved patient compliance above 90% at our established clinics, well beyond the industry average. Regarding medical transportation, I'm happy to share that all of our geographic regions were profitable and expanding in June. We've worked hard to remove medical transportation business lines that weren't profitable, and we plan to continue through year-end transitioning most of this business to our creative leased hour model. We substantially improved profitability in this segment and accomplished that while revenues rose 105% compared with the same period last year; we feel this presents a strong chance to demonstrate our value to healthcare systems and possibly grow those relationships through our mobile health offerings. Right now our backlog is $325 million, spread across roughly three years. That's up from $205 million as of May 8th this year, when we last reported. The entire rise in backlog, along with the guidance, comes from growth in our mobile health segment. Before I turn things over to Norm, I'd like to spend a moment restating that we have a substantial number of new contracts and partnerships either signed very recently or close to launching, and we're putting investment behind the enormous opportunity in front of us. We feel DocGo has been positioned strategically to draw on cash flows from our core municipal contracts to fund this growth internally, and that strategic plan is coming together beautifully. At this point I'll pass things over to our CFO, Norm Rosenberg, so he can walk us through the financials. Norm?
Norm Rosenberg
executiveThank you, Lee. Good afternoon, everyone. For the second quarter of 2023, total revenue came in at $125.5 million — the highest quarterly revenue figure in DocGo's history — which works out to an 11% rise over the first quarter and a 15% rise over the second quarter of 2022. The second quarter of last year contained an estimated $28 million in mass COVID testing revenues. In contrast, during 2023's second quarter, mass COVID testing revenues made up a relatively insignificant share of total revenues. If you strip out those testing revenues from both periods, recurring revenues grew by more than 50% versus the prior year period. Mobile health revenue in the second quarter of 2023 was $80.1 million, nearly 10% above the first quarter and 8% below last year's second quarter. But again, if we look at recurring mobile health revenues by taking out mass COVID testing revenues of less than $1 million for the second quarter of 2023 and $28 million for the second quarter of 2022, mobile health revenues rose 33% versus the prior year period. Medical transportation revenue climbed significantly, reaching $45.4 million in Q2 of 2023 — 13% higher than the first quarter and more than double the transport revenues we posted in the second quarter of 2022. Almost every core transportation market saw revenue growth both year-over-year and sequentially, carrying forward the momentum from the second half of last year. In the second quarter, mobile health revenues represented about 64% of total revenues, with transport making up the remaining 36%. Judging by the first five weeks of the third quarter, it looks like mobile health could represent over 70% of revenues in the third and fourth quarters of this year. We posted net income of roughly $1.3 million in Q2 2023, versus a net loss of $3.9 million in the first quarter and net income of $11.8 million in the second quarter of 2022. Last year's second quarter included approximately $4.4 million in non-recurring income tied to the remeasurement of warrant liabilities and finance lease obligations. Adjusted EBITDA for the second quarter of 2023 was $9.1 million, compared with Adjusted EBITDA of $5.6 million in the first quarter and $12.3 million in last year's second quarter. Total gross margin in the second quarter of 2023 came to 33.4%, more than 500 basis points above the 28.1% gross margin we recorded in Q1 of this year, and compared with 35.9% in the second quarter of 2022. In the second quarter of 2023, gross margins from the mobile health segment were 34.9%, significantly better than the 27.7% gross margin mobile health recorded in the first quarter of this year, and compared with 39.9% for the second quarter of 2022; in the transportation segment, gross margins kept expanding, rising to 30.7% in Q2 2023, up from 28.9% in the first quarter and from 20.2% in Q2 of 2022. Gross margins came in higher sequentially for the second quarter versus the first, which was what we had expected, since some of the margin headwinds from earlier in the year eased — notably the startup costs tied to certain mobile health projects. We did also see some project startup costs in Q2, in mobile health as well as in the transportation segments. We expect gross margins to keep improving on a sequential basis as we head into the third and fourth quarters of this year, though overall margins may be affected by the timing and the size of projects that are newly launched and ramped up. Turning to operating costs. Operating expenses came to 32.1% of total revenues in the second quarter of 2023, versus 34.2% in the first quarter and 29.1% in the second quarter of 2022. A factor behind operating expenses was higher stock-based compensation expense — predominantly options rather than restricted stock units — as we work to refine our compensation structure so that it better aligns the interests of shareholders with those of employees across all levels of the company. On a year-over-year basis, excluding depreciation and stock comp expenses, operating expenses represented 26.3% of total revenues in the second quarter of 2023, a slight increase from 25.4% in the second quarter of 2022. Since we expect revenues to rise in the second half of 2023 relative to the first half of 2023, we anticipate operating expenses falling as a percentage of total revenues, which should drive operating margin expansion during the second half of the year. Beyond these scale-related benefits, we are advancing on margin enhancement projects across many of our business lines, as we have laid out over the last couple of quarters. Now, on to the balance sheet. At June 30, 2023, total cash and cash equivalents, including restricted cash, stood at $123.8 million, versus $127.5 million at the close of Q1. Even though margins are improving, as I mentioned earlier, we still face working capital requirements as we grow our business with larger, more creditworthy municipal customers — New York City, for instance, received a credit rating upgrade in 2023 — and these customers carry longer payment terms and a longer payment cycle during the initial stages of a project. We intend to deploy our balance sheet to invest in growing the business. In making these growth investments, we seek to balance our wish to generate financial returns against our need to deliver societal returns by positively affecting the lives of as many people as we can. Even with those working capital needs—which will probably continue given how fast we're growing—June was the largest collections month we've ever had. That let us finish the quarter with total cash very near where it stood at the close of Q1. It also brought a 10% reduction in accounts receivable versus the Q1-end figure. Together with higher sequential revenue in Q2, that meant days sales outstanding—our DSO—fell by almost 20 days, returning to the level we were used to. Digging a little further into the receivables book, as of June 30th over 50% of the total was current, meaning under 30 days old. At the close of the 1st quarter, only about 30% was under 30 days. Quarter by quarter, our receivables are getting healthier. Moving on to the outlook for the back half of 2023, we expect demand to remain strong among customers in both the mobile health and transportation services segments. Early Q3 performance has us quite encouraged: the revenue momentum from the later part of Q2 carried into July, which stood far and away as our best revenue month so far. As Anthony noted, with that strong momentum plus better visibility through year-end, we're lifting full-year revenue guidance to $540 million-$550 million, versus the $500 million-$510 million range we most recently gave. At the new range, that's roughly 23%-25% year-over-year top line growth compared with 2022 full-year figures on an as-reported basis. But if we strip the $75 million of mass COVID testing out of the 2022 revenue baseline, and keep in mind that we don't anticipate any material mass COVID testing revenue in 2023, we'd be looking at top line growth of approximately 50% year over year; we're also raising Adjusted EBITDA guidance to $48 million-$53 million, up from the original $45 million-$50 million range. We continue to expect a gross margin of approximately 37% as we exit 2023, with margins improving sequentially through year-end. The revenue and EBITDA guidance implies EBITDA margins that expand in the second half versus the first half. This forecast rests on two elements. First, as we've said for a couple of quarters and as Q2 showed, we expect gross margins to rise sequentially as we keep addressing the factors that temporarily pushed gross margins down in this year's first quarter. Second, we expect operating expense growth to run well under the sequential revenue growth rate, especially when it comes to compensation, on both a cash and a stock-based compensation basis, which should drive the margin expansion we anticipate as greater top-line scale is achieved. Now, I'd like to hand the call back over to Anthony.
Anthony Capone
executiveThank you, Norm. Before we move on to Q&A, I wanted to take just a moment to address the recent New York Times piece that criticized our partnership with New York City aimed at delivering healthcare and basic services to migrant populations in upstate New York. Please understand, DocGo's core ethos is delivering high-quality healthcare to those who need it most, frequently accomplishing what seems impossible for our customers by deploying rapidly in response to unprecedented events. In the earliest phase of this migrant work, we were standing up projects on extraordinarily tight timelines. The purpose behind all of this was preventing families and children from sleeping on the streets without healthcare or basic necessities. Each day, DocGo saves lives, treating and transporting many thousands upon thousands of patients. Among the many key facts omitted from the New York Times article was the most recent weekly polling of over 500 migrants in our care, which indicates that more than 85% of them feel they are being supported and that their needs are being met. City officials know well how successful this program has been, as shown last week when Mayor Adams restated his confidence in our partnership at a press conference, where he commended our work and characterized it as a Herculean effort to assist the city with this humanitarian crisis. I feel tremendous pride in what we are doing alongside the city and our partners upstate, particularly all the remarkable hard work being done by local CBOs, with whom we collaborate every day. All of us are working hard to preserve these migrants' basic human dignity and to help change their lives for the better. To the thousands of DocGo employees listening, over 2,000 of whom are shareholders, the work you do matters. Every day, your efforts are helping some of the world's most vulnerable and helpless citizens find safety, support, and a better life. You should take pride in the work you do. I certainly do. I'll hand it back over to the operator for questions.
Richard Close
analystYeah, thanks for those questions. Regarding that $325 million backlog, I just want to be clear — does any of the New York City asylum contract fall within it, or does it only cover a portion of that contract? It would help to have that clarified.
Norm Rosenberg
executiveYeah. Hey, Richard, Norm here. Give me a moment, really, to sort of walk you through the way we view our backlog.
Richard Close
analystYeah.
Norm Rosenberg
executiveYeah, so how the backlog generally functions is like this. What we do is begin with... When we say we're starting at roughly $205 million from the previous time, you should know that a substantial portion of that $205 million moved out of backlog and turned into real revenue over the quarter. The, the, the added growth is actually bigger than the, the two — going from $205 to $325. It does take in a lot of that specific contract, but it also takes in probably 12 separate items that turned into backlog during, during that period.
Richard Close
analystAll right, that helps. I had a question about the care gap programs — it's good to see you're, I suppose, being assigned lives in that area instead of, as you might say, needing to go out and build lead flow and so forth. Could you speak a bit about, say, what revenue contribution you expect from those care gap programs, whether for 2023 or once you're, like, fully ramped?
Anthony Capone
executiveRichard, this is Anthony. Reimbursement on those comes to roughly $250 for each care gap closure. What remains to be seen — and we'll share considerably more detail on our next earnings call — is, you know, the number of patients who, you know, end up compliant with our program by closing these care gaps. That really will be the deciding factor. As you know, we've announced that roughly 73,000 initial lives are being assigned to us. The average is about $250 per individual care gap closed. A number of them have multiple gaps that must be closed, which means multiple visits. The, the, you know, element we'll be proving out over the course of this quarter is how many of them we can actually close.
Norm Rosenberg
executiveThere's nothing material really in our revenue guidance.
Anthony Capone
executiveOne key point is that essentially none of the raised guidance stems from those care gap closure programs.
Sarah James
analystThank you. I was hoping we could get a bit more detail on the increase to revenue guidance. I know in the release you mentioned that this reflects a prudent look at run rate and new business. For contracts you signed recently, such as New York HPD or others that are more fee for service, how should we think about what is baked into your 2023 guidance regarding the ramp on those?
Anthony Capone
executiveIt's essentially what we're doing today, extended forward. Unless, of course, we have something that is guaranteed, so we have a specific launch date in the future; we do have contracts with a scaling timeline that states, "Okay, on this date, you will add this number of ambulances or add this number of mobile health units," and in that case that will then be reflected in higher revenue guidance. It's either, A, a certain launch date, or B, simply taking what we are doing today as of, you know, a couple days ago and projecting that through the end of the year. When we have greater confidence, but not certainty, in future revenue, that's when we'll add that to the backlog rather than raising the guidance.
Sarah James
analystGreat. Could you expand a bit on what the future might hold for the care gap closure program? When it comes to these attributed lives, is there potential to convert them into situations where you'd have chronic care management continuing on an ongoing basis, or perhaps eventually look to underwrite the risk for any attributed primary care life? How does the future of that program shape up?
Anthony Capone
executiveYeah, exactly right. The way the contracts are structured, the majority of these individuals not only have... Or let me step back for a moment. The reason they get assigned to us — DocGo's particular niche — is for individuals with care gaps, since they haven't seen their primary care provider in more than a year; that means they need care. So when we enter the home, we deliver that care, whether it's a diabetic retinal exam or diabetic foot exam or their annual A1C. Then we also say, "Okay, well, you're typically polychronic," and then we'll offer, if they meet the medical necessity, to have them monitored, RPM, and then, you know, managed through CCM, as well as potentially becoming their attributed PCP. Once you become their attributed PCP, there's the possibility of potentially taking on increasing increasing opportunities with that payer, as you normally would as a PCP. That's obviously something we'll evaluate in the future. It's not something we're doing right now. Our goal right now is to just simply close as many gaps as possible, and then to enlist patients that will have the greatest need into our monitoring and management services.
Matt Shea
analystHi, Matt Shea here filling in for Ryan. Appreciate you taking our questions, and congratulations on the strong quarter. I wanted to dig into a bit of the commentary from earlier on the call. Anthony, it kind of sounds as though with certain of these newer deals, they differ from prior deals, in that you may begin smaller and ramp over time in a more structured fashion, with fixed dates for scaling up. I'm curious whether that's a deliberate choice you've been making in your new contracts — meaning you don't need such steep upfront starting costs; and if so, how does that shift your expectations regarding the sort of impact these new and bigger deals might have on the margin line? Might we see a future where certain of these deals are closer to gross margin neutral at the outset, instead of negative right from day one?
Anthony Capone
executiveMy sense is the contracts themselves and their ramp schedules haven't shifted meaningfully, you know, comparing the past with today. What I believe has shifted is that we're now seeing payoffs from our rapid normalization initiative, which we launched in Q1 and sort of carried through Q2, and at this point we're truly nearing the completion of phase one of that rapid normalization initiative. We're genuinely seeing those payoffs, since those represent durable contractual changes in how we engage with subcontractors, along with changes involving our fleet. You know, I've gone over all of those points previously, but, you know, looking at certain new projects we kicked off in Q2, they were already beginning to capture the benefits of that rapid normalization project, because those improvements, they reach across the whole company. They weren't merely one-off fixes. We didn't slap Band-Aids on a few marginal issues. We changed how we operate at a fundamental level. At this point we can launch at the same pace, yet without the same margin pressures; that isn't to say there are no startup costs; we still have a phase two of the rapid normalization initiative, which we'll kick off, you know, likely in later Q3, but we've reduced them quite substantially. If you look at the marginal improvement from Q1 to Q2, you know, nearly 500 basis points, most of that stems from the success of the rapid normalization project.
Matt Shea
analystGot it. Makes sense.
Anthony Capone
executiveSure.
Matt Shea
analystI just wanted to follow up on that. And then, on another win that possibly received less attention, the Dara Transport Network. I'd really like to hear a bit more about it — what it would take for you folks to kind of see the supply side and the demand side of that network, and then, as it expands, what sort of revenue or margin expectations you might have for it?
Anthony Capone
executiveYeah, that's a good question. The Dara Transport Network is really something we rolled out with our current customers. Right now we have no plans to simply convert that into an entirely separate product line that gets offered. The way this truly distinguishes us when we go into health systems is that we can function as a provider and at the same time work alongside the providers already in place there. That makes the sale much easier and gives them more confidence, since going with DocGo doesn't have to be all or nothing. They can tell us, "We'll hand DocGo 70% of the work, but we want to retain these other two or three vendors." Our response is, "No problem. We're not greedy. We'll collaborate with them. They're welcome to join." You're going to get that same degree of visibility, the same simplicity when placing orders, and, you know, reporting over the long term; all of us can hold one another accountable." Whenever we bring on a new customer, that offering is among the flagship ones we roll out with; we also go out, and if they tell us, "We'd like others to," you know, then we'll bring additional providers onto the platform, and we do it in a manner that genuinely aims to make it fully integrated with those other providers' systems, so that we can... You know, the reality is that within the transportation section, demand substantially exceeds supply. We see no obstacle to everyone collaborating—competition can remain—to serve hospital patients. Achieving that requires all of us inside a single system beneath one roof. That is essentially what the Dara Transport Network represents.
Michael Latimore
analystYeah, great. Thanks. Yeah.
Michael Latimore
analystSolid results and a strong outlook here. I suppose, could you shed a little more light on the Sidely Care deal? What portion of that deal's maximum amount has landed in backlog, if you can share that?
Norm Rosenberg
executiveWell, Mike, I think the first thing you've got to do is, you know, with the figure that everybody's looking at, which is out there, it's roughly $430 million. I think the first thing you need to do is adjust that figure by—or sort it into categories of the amounts that are going to be spent that represent actual recorded revenue, right? There's revenue recognition. A portion of that represents flow-through. Our estimate for the revenue to be captured is roughly $300 million. I'd say approximately two-thirds of it is already baked into our backlog, and the remainder becomes — with a slight modifier applied to that $300millionand then there's a small piece that obviously has already been realized and that we would expect to realize in Q3 and Q4. It's a little bit tricky, and Anthony started to explain this earlier, but it's a little bit tricky to figure out how to put something in backlog versus putting something in the revenue guidance. Basically, when we give revenue guidance, that's a projection — our most informed estimate of what revenues from various projects will total, combined, between now and year-end or across the entire year. Backlog, on the other hand, covers anything deemed achievable that may not have started yet. As with lots of other projects, this one comes with multiple phases. Some phases are underway at present, and various sites are being served. We can begin projecting that forward and fold it into the revenue guidance, while the remaining sites that haven't started up yet would usually land in backlog. It isn't fully accurate to describe it as 100% that way, though conceptually that's essentially what it is. On one side, we examine how current work will grow, and that feeds into revenue guidance; on the other, we consider additional items we anticipate launching at some stage, and those would land in backlog.
Michael Latimore
analystAll right, understood.
Norm Rosenberg
executiveMost of that figure consists of backlog.
Michael Latimore
analystYeah. OK, great. So this is significant — potentially very significant. If you win another one of similar scale — say, border control or something like that — how are you thinking about handling that extra demand and, and growth? I mean, do you believe you can find enough supply, you know, labor, you know, are there specific challenges there? Like, how, how would you prepare for something if you land another deal of this size?
Lee Bienstock
executiveYeah, well, it would involve a whole range of different factors. Hey, hi, Mike, this is Lee. I think it would involve a whole range of different factors. Naturally, location plays a major role there. Naturally, when we expand into a fresh region with a fresh group of clinicians and staff, naturally, that gives us a chance to draw on extra personnel and extra resources and new regions; that would be the first part. To illustrate, the case you mentioned is the border patrol, which is naturally beyond New York, so that would mean expanding for us in a new area with a new set of staff; that's the first part. The second part is, I believe we've truly rounded out our management team up to now, and Norm brought that up regarding our SG&A investments. We genuinely believe our management team is quite robust and capable of expanding both our existing projects and the new ones we’re able to introduce. We have truly strengthened that team. We’ve also truly strengthened our directors nationwide across every geography we operate in, and those directors are highly capable. Our leadership group is highly capable, and we believe there is further leverage to be gained and further scale to be achieved — that the investment made in those management ranks can genuinely be used to grow and scale from this point onward.
Anthony Capone
executiveLet me just build on what Lee mentioned. Regarding staffing in particular, the approach we developed for staffing and growth is really quite scalable, since the agencies we work with represent many hundreds of thousands of clinicians and providers in total across the United States. Being able to draw on that network, while doing so via our new contractual relationships, lets us incur only a higher start-up cost for a brief period, which is why we have strong confidence that if we win a large contract of that kind, we can manage it.
Michael Latimore
analystOkay. Thanks a lot. Best of luck.
Lee Bienstock
executiveThanks.
David Grossman
analystThanks. Good afternoon. I realize there have been plenty of questions about the backlog and all of that, so I don't want to drag this topic out endlessly, but let me just make sure we're clear: when you consider the 325, should we assume the conversion into revenue happens in a fairly linear way, or how would you like us to think about the way that turns into revenue?
Anthony Capone
executiveDavid, it's Anthony here. Just so I understand, by convert do you mean in terms of, say, a timeline? As in, what chronology do you have in mind?
David Grossman
analystYeah.
Anthony Capone
executiveOf the 325?
David Grossman
analystYes, precisely. Correct, precisely.
Anthony Capone
executiveYeah, so a big chunk of that rise you're seeing is going to tie back to the HPD contract, and that HPD contract runs through, you know, May of next year; so that's the source of it. Now, the backlog amount we had before, that was roughly a close to a three-year ramp, and that was, as you said, mostly linear. The backlog increase, not every bit of it, but the bulk of it, ties to the HPD contract, and that contract spans... It went from May of 2023 to May of 2024.
Norm Rosenberg
executiveYeah, and hey David, this is Norm. Even so, some factors are going to interfere with that straight-line pattern. For instance, a major piece of our backlog from a couple of quarters back was the transport contract with NYC Health + Hospitals, and we knew it represented a specific dollar figure spread across a 3-year span. We did recognize some revenue from that contract during the quarter, and it came mostly in the latter portion of the quarter. Looking ahead to Q3, we'll bring in more revenue from that project in Q3, since we'll have a full quarter of it rather than what we had in Q2; it begins to turn linear. What will interfere with that being entirely smooth, and will make it somewhat lumpy, is that when these projects ramp up at, you know, a mid-quarter point in time, then you're going to, you know, see some lumpiness there where you have that first quarter or second quarter out as it converts from backlog into revenue, where you'll have a comparatively small figure, but then it's really going to pick up speed.
David Grossman
analystI'm not really looking for you to give guidance on next year, but I think we all wonder what those comparisons will look like, especially given that asylum contract, which can be so big during the first 12 months. I realize there's a renewal option, but how would you like us to think about what comes after May of 2024 with that contract?
Anthony Capone
executiveI'd approach it from a human angle. Without getting into the contractual details, the great majority — I believe 85%-86% — of the people in our care are families with children. So the idea that these families with children would simply be turned out onto the street with no care, that social work services and case management would no longer be required, strikes me as extremely unlikely. That said, I do believe there could be a change, and you might see single adults perhaps stop receiving the same services, but I find it extremely improbable that families with children — who again make up more than 85% of the individuals arriving in New York — would ever be left without those services.
David Grossman
analystAt what point do they become eligible?
Norm Rosenberg
executiveThat existing agreement stays in effect until May.
David Grossman
analystGo ahead. I'm sorry.
Lee Bienstock
executiveGo ahead, David.
Norm Rosenberg
executiveNo, I was simply pointing out that the existing agreement goes until May. That already carries us into a portion of 2024. Please continue.
David Grossman
analystRight. Right.
Norm Rosenberg
executiveRight.
David Grossman
analystAt what point do they truly become eligible — I mean, Medicaid eligibility — is that a political matter, or is there some sort of route for them, you know, to receive treatment through Medicaid?
Anthony Capone
executiveYes, there is. After they've filed their asylum application in New York, you know, under a range of circumstances, they're able to qualify for New York State Medicaid just like ordinary Medicaid enrollees. It covers, you know, the full set of Medicaid benefits — primary care, urgent care, and similar services. If they show up at a hospital before filing that asylum application, then they get enrolled in something called Emergency Medicaid. That's, that's really only covering emergency-type situations. What we're doing with these, these groups is working to remain their care provider well beyond this program. When they arrive, you know, we're striving to ensure they can get into health plans matching their eligibility. And after that occurs, we can serve as their attributed PCP and keep caring for these people for as long as they need that care.
David Grossman
analystUnderstood; so my remaining question is this — you mentioned margin improvement during the latter half of the year, and I believe I follow those dynamics. Would it be fair to consider the exit rate in 2023 a sensible predictor of where margins should begin in 2024? Or are there seasonal and contractual factors suggesting that isn't quite the right framework?
Norm Rosenberg
executiveNo, David, I'd say your assumption holds up well, largely because when we consider that exit rate, we aren't viewing it through the lens of particular non-recurring or seasonal items that will occur, you know, during the fourth quarter or in December. It's genuinely just a question of scanning ahead, attempting to determine when we reach — to use that phrase once more — a more normalized margin. You know, if that were the exit rate for 2023, then from a modeling perspective at least, that does become the starting point for 2024 in our thinking.
David Grossman
analystRight. So, with the second phase of the changes you're making to your model for the normalization project, do those benefits show up in Q2, or should we view that as a 2024 tailwind?
Anthony Capone
executiveNo, I think those benefits will become visible for you during the first half of 2024.
David Grossman
analystUnderstood. Excellent. Fine, everyone. Many thanks.
Lee Bienstock
executiveAppreciate it, David.
Anthony Capone
executiveDavid.
Kieran Ryan
analystHey there, everyone. Kieran Ryan here on behalf of Pito. Appreciate you taking my question. I'd like to start with the transportation piece. Is there any reason that the increase in segment margins shouldn't be treated as a fresh run rate from here on out, with room to, you know, climb even further as the leased hour mix keeps growing?
Lee Bienstock
executiveYes, that is definitely what's driving the margin on the medical transportation side; we're converting new con— Well, all new contracts signed are leased hour, and even for old contracts, we're going back and converting those over to leased hour, which clearly is lifting margins; we, we expect it to remain where it is and rise as we, as we improve the, the mix on the transportation side, it's really getting better.
Norm Rosenberg
executiveSure, there are plenty of positive developments happening somewhat out of direct view that are pushing that figure upward, and many of them are visible in our 10-Qs and other disclosures. Our average price per trip keeps climbing, and that's driven not merely by broad inflation — it reflects that we're handling additional ALS trips or CCT trips relative to BLS trips, and that the acuity of the trips we take is higher. What we're doing is really what I'd describe as portfolio management, correct? That applies both to how the mix of trips looks and to how the mix of different markets looks. As we've discussed, we exited the California transport market, and that step by itself lifts our margin. Lee referenced this during his prepared remarks a few minutes back — we're reviewing every one of our transport markets and figuring out which have the scale required for us to keep operating there and which have the margin profile required to keep operating there. Once you undertake that sort of pruning, it becomes almost self-fulfilling, in that margins rise. So to sum up and answer your question, yes, we regard the figure we're seeing now as a launching pad toward a stronger figure ahead. And it truly stems from a great many separate margin enhancement projects carried out across the last 12 months-18 months.
Kieran Ryan
analystGreat, thanks. So, turning to the RPM side, I was just curious whether you have any thoughts at this point on your early efforts there — what sort of traction are you seeing with customers, and how significant a part of the discussions is that service line in some of these new deals you're negotiating? Thanks.
Lee Bienstock
executiveYeah, oh, absolutely, Kieran. Yeah, RPM keeps featuring in every one of the new deals on the mobile health side, especially with the care gap closure programs and our payer partnerships. What it's ultimately there to do is bring down the cost of care, deliver proactive care, and keep patients out of the hospital. When we go and do care gap closure, which we talked about — all those care gap closure services we provide — if we do see candidates, if we do visit patients who are good candidates for our RPM platform, that's when we would enroll them; we're already in their home. We'd enroll them in the program, and then, obviously, we'd start monitoring them from there. It's absolutely symbiotic with our care gap closure programs, with a lot of our mobile health deployments, and it keeps being a big driver for us, for the future. We're excited about it.
Kieran Ryan
analystThanks, guys. Appreciate it.
Richard Close
analystYeah, thanks for following up. Norm, is there any way you can help us see the transport volumes and the pricing that'll be in the queue?
Norm Rosenberg
executiveThat's not something I have at my fingertips, but we'll get the queue out there. It'll be available in the queue inside 24 hours. Just so you have a sense, volumes rose — double digits when I compare Q2 to Q2, and I think possibly even above... possibly even beyond 20%, though certainly double digits. Average price year over year climbed as well. I'd rather not give you a figure that could turn out incorrect, though I can share the general direction. The exact number will be available tomorrow.
Richard Close
analystAlright. Regarding free cash flow — I appreciate what you said about the collections in Q2, the DSOs, and so forth. How are you viewing free cash flow, perhaps the conversion of Adjusted EBITDA into free cash flow, for the year?
Norm Rosenberg
executiveWell, first let's take stock of where we stand at the halfway mark, and as usual we did include the cash flow statement in the earnings release. Given how much working capital has affected our results and our operating cash flow, what I prefer to do is break the operating cash flow piece into two parts. There's the net income or net loss, so to speak, plus the add-back of non-cash items — that's one part — and then there are the changes in the working capital categories, which gives you some sense of things. The working capital side is going to keep being a drag. If you examine the first half of the year, the entire negative on the operating cash flow side, and more, came out of the working capital category; we saw a $14 million-$15 million increase in AR compared with the end of the year, and a $14 million-$15 million decrease in accounts payable, so we truly had a large negative cash cycle there. When you look at the cash flow generated from operations — what I tend to call the P&L cash flow — I believe it came to roughly $16 million in the first half of the year, which is about what we had been running at when we think about being able to generate $30 million-$40 million of operating cash flow. If we reached a point where working capital had a net zero effect, that's roughly the cash flow generation you'd be looking at. I would set the $14.7 million, I think that was the figure, of Adjusted EBITDA we generated in the first six months of the year against about $16 million of P&L cash flow, right, excluding the impact of the working capital categories over that same period; it matches up fairly well. Roughly $60 million in the first half of the year.
Richard Close
analystAll right, thanks.
Anthony Capone
executiveWe appreciate everyone joining us for this earnings call. To any investors on the line who have follow-up questions, please get in touch with Mike Cole and arrange one-on-one meetings. Thank you.
Operator
operatorAppreciate that, sir. Everyone, that brings us to the end of today's call. Thanks for being with us. You can go ahead and disconnect your line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.